BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37976999)

  • 1. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
    Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
    ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Avelumab First-line Maintenance Therapy for Advanced Urothelial Carcinoma: Comprehensive Clinical Subgroup Analyses from the JAVELIN Bladder 100 Phase 3 Trial.
    Grivas P; Park SH; Voog E; Caserta C; Gurney H; Bellmunt J; Kalofonos H; Ullén A; Loriot Y; Sridhar SS; Yamamoto Y; Petrylak DP; Sternberg CN; Gupta S; Huang B; Costa N; Laliberte RJ; di Pietro A; Valderrama BP; Powles T
    Eur Urol; 2023 Jul; 84(1):95-108. PubMed ID: 37121850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
    Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
    Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practice.
    Grivas P; Agarwal N; Pal S; Kalebasty AR; Sridhar SS; Smith J; Devgan G; Sternberg CN; Bellmunt J
    Cancer Treat Rev; 2021 Jun; 97():102187. PubMed ID: 33839438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma.
    Hoffman-Censits J; Grivas P; Powles T; Hawley J; Tyroller K; Seeberger S; Guenther S; Jacob N; Mehr KT; Hahn NM
    Future Oncol; 2024 Feb; 20(4):179-190. PubMed ID: 37671748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Avelumab as First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma.
    Mansinho A; Cruz A; Marconi L; Pinto C; Augusto I
    Adv Ther; 2023 Oct; 40(10):4134-4150. PubMed ID: 37608243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis.
    Tomita Y; Yamamoto Y; Tsuchiya N; Kanayama H; Eto M; Miyake H; Powles T; Yoshida M; Koide Y; Umeyama Y; di Pietro A; Uemura H
    Int J Clin Oncol; 2022 Feb; 27(2):383-395. PubMed ID: 34973108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up.
    Powles T; Park SH; Caserta C; Valderrama BP; Gurney H; Ullén A; Loriot Y; Sridhar SS; Sternberg CN; Bellmunt J; Aragon-Ching JB; Wang J; Huang B; Laliberte RJ; di Pietro A; Grivas P
    J Clin Oncol; 2023 Jul; 41(19):3486-3492. PubMed ID: 37071838
    [No Abstract]   [Full Text] [Related]  

  • 9. Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma.
    Grivas P; Kopyltsov E; Su PJ; Parnis FX; Park SH; Yamamoto Y; Fong PC; Tournigand C; Climent Duran MA; Bamias A; Caserta C; Chang J; Cislo P; di Pietro A; Wang J; Powles T
    Eur Urol; 2023 Apr; 83(4):320-328. PubMed ID: 35654659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical evidence and insights supporting the use of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in the Asia-Pacific region.
    Eto M; Lee JL; Chang YH; Gao S; Singh M; Gurney H
    Asia Pac J Clin Oncol; 2022 Oct; 18(5):e191-e203. PubMed ID: 35238147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Analysis from JAVELIN Bladder 100 by Duration of First-line Chemotherapy and Interval Before Maintenance.
    Sridhar SS; Powles T; Climent Durán MÁ; Park SH; Massari F; Thiery-Vuillemin A; Valderrama BP; Ullén A; Tsuchiya N; Aragon-Ching JB; Gupta S; Petrylak DP; Bellmunt J; Wang J; Laliberte RJ; di Pietro A; Costa N; Grivas P; Sternberg CN; Loriot Y
    Eur Urol; 2024 Feb; 85(2):154-163. PubMed ID: 37714742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response and Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy (PBC) in Patients With Advanced Urothelial Carcinoma (aUC): "Real World" Experience.
    Bakaloudi DR; Talukder R; Lin GI; Makrakis D; Diamantopoulos LN; Tripathi N; Agarwal N; Zakopoulou R; Bamias A; Brown JR; Pinato DJ; Korolewicz J; Jindal T; Koshkin VS; Murgić J; Miletić M; Frobe A; Johnson J; Zakharia Y; Drakaki A; Rodriguez-Vida A; Rey-Cárdenas M; Castellano D; Buznego LA; Duran I; Carballeira CC; Barrera RM; Marmorejo D; McKay RR; Stewart T; Gupta S; Ruplin AT; Yu EY; Khaki AR; Grivas P
    Clin Genitourin Cancer; 2023 Oct; 21(5):584-593. PubMed ID: 37414620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma.
    Lapuente M; Conway D; Wood LS; Kehoe K; Carroll Bullock A; Devgan G; Burns KD
    Clin J Oncol Nurs; 2023 Jan; 27(1):71-80. PubMed ID: 37677821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
    Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
    BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact
    Bueno APA; Clark O; Turnure M; Moreira ES; Chang J; Hou N; Li S; Kim R; Kearney M; Kirker M; Kanas G
    Future Oncol; 2024 Mar; 20(10):613-622. PubMed ID: 37357780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis.
    Apolo AB; Ellerton JA; Infante JR; Agrawal M; Gordon MS; Aljumaily R; Gourdin T; Dirix L; Lee KW; Taylor MH; Schöffski P; Wang D; Ravaud A; Manitz J; Pennock G; Ruisi M; Gulley JL; Patel MR
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer.
    Powles T; Park SH; Voog E; Caserta C; Valderrama BP; Gurney H; Kalofonos H; Radulovic S; Demey W; Ullén A; Loriot Y; Sridhar SS; Tsuchiya N; Kopyltsov E; Sternberg CN; Bellmunt J; Aragon-Ching JB; Petrylak DP; Laliberte RJ; Huang B; Costa N; Blake-Haskins JA; Grivas P
    Future Oncol; 2022 Jun; 18(19):2361-2371. PubMed ID: 35416053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses.
    Wood LS; Conway D; Lapuente M; Salvador G; Fernandez Gomez S; Carroll Bullock A; Devgan G; Burns KD
    J Infus Nurs; 2022 May-Jun 01; 45(3):142-153. PubMed ID: 35537002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Kikuchi E; Hayakawa N; Nakayama M; Uno M; Nakatsu H; Kitagawa C; Miyake H; Yamada T; Fujita K; Shimoyama H; Nishihara K; Kobayashi M; Nakamura M; Fujimoto K; Sano T; Nishiyama N; Ito T; Kajita M; Kobayashi T; Kitamura H
    Int J Urol; 2024 May; ():. PubMed ID: 38722221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
    Gross-Goupil M; Domblides C; Lefort F; Ravaud A
    Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.